Stephens Consulting’s Regeneron Pharmaceuticals REGN Stock Holding History

Stephens Consulting’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$772	Buy	+1	New	+$679	﹤0.01%	414
2025 Q3	–	Sell	-3	Closed	-$1.57K	–	986
2025 Q2	$1.57K	Buy	+3	New	+$1.67K	﹤0.01%	554
2025 Q1	–	Sell	-21	Closed	-$15K	–	1550
2024 Q4	$15K	Hold	21	–	–	﹤0.01%	307
2024 Q3	$22.1K	Sell	21 -4	-16%	-$4.45K	0.01%	253
2024 Q2	$26.3K	Buy	+25	New	+$24.2K	0.01%	240
2023 Q4	–	Sell	-100	Closed	-$82.3K	–	502
2023 Q3	$82.3K	Buy	+100	New	+$78.6K	0.03%	125
2022 Q4	–	Sell	-29	Closed	-$20K	–	543
2022 Q3	$20K	Hold	29	–	–	0.02%	252
2022 Q2	$17.1K	Hold	29	–	–	0.01%	261
2022 Q1	$20.3K	Hold	29	–	–	0.02%	269
2021 Q4	$18.3K	Buy	+29	New	+$17.8K	0.02%	311

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Stephens Consulting's REGN Position: Q4 2025 in Review

Stephens Consulting opened a new position in Regeneron Pharmaceuticals (REGN) in Q4 2025: 1 share worth $772. The stake represents ﹤0.01% of the portfolio and ranks #414 among its holdings. This is a return to the name: Stephens Consulting previously reported a position in REGN as recently as Q2 2025.

Stephens Consulting first reported a position in REGN in Q4 2021 and has held it in 10 quarters since. The position peaked at $82.3K in Q3 2023. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Stephens Consulting held 1 share of Regeneron Pharmaceuticals worth $772 as of Q4 2025.
Regeneron Pharmaceuticals was a new Stephens Consulting position in Q4 2025.
Regeneron Pharmaceuticals made up ﹤0.01% of Stephens Consulting's portfolio in Q4 2025, its #414 holding.
Stephens Consulting first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
Stephens Consulting's Regeneron Pharmaceuticals position peaked at $82.3K in Q3 2023.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Stephens Consulting's 13F filing for Q4 2025, filed 13 Jan 2026.